In clinical practice, it is necessary to strictly distinguish between groups of patients with asymptomatic bacteriuria (ABU) and urinary tract infection (UTI) based on standard and additional criteria, as well as to determine absolute indications for the use of antibacterial drugs in order to prevent their side effects and development of antimicrobial resistance. Objective. To perform a differential diagnosis of ABU and UTI in patients with liver cirrhosis (LC) based on blood and urine laboratory data. Material and methods. A prospective observational study was conducted on 338 hospitalized patients with LC aged 55.00 (45.00; 63.00) years, including 189 (55.92%) men and 149 (44.08%) women. The patients were classified as class A – 78 (23.08%), class B – 118 (34.91%), and class C – 142 (42.01%) individuals. The study included standard research methods in accordance with the Clinical Protocol as well as the determination of lactoferrin, Kidney Injury Molecule 1 (KIM-1), Neutrophil Gelatinase Associated Lipocalin (NGAL) in urine, homocysteine, and lipopolysaccharide-binding protein (LBP) in blood. The study was registered in Clinicaltrials.gov (NCT05335213). Results. In hospitalized patients with LC, the incidence of UTIs was 37.87%, and that of ABU – 23.96%. The levels of bilirubin, leukocytes, erythrocyte sedimentation rate, C-reactive protein (CRP), blood ferritin, total protein, urinary lactoferrin, NGAL, and KIM-1 in patients with LC and UTI were significantly higher, while the levels of blood albumin, hemoglobin and prothrombin index (PTI) were lower compared to those with ABU (p<0.05). When conducting differential diagnosis between ABU and UTIs in patients with LC, additional criteria for UTI may be: blood leukocyte level ≥8.6×109/l (diagnostic efficacy (DE) – 75.08%, AUC=0.759), CRP ≥12.45 mg/l (DE – 72.19%, AUC=0.718), albumin ≤28.35 g/l (DE – 73.11%, AUC=0.776), PTI <0.69 (DE – 71.29%, AUC=0.758), and urinary NGAL ≥38.27 ng/ml (DE – 68.74%, AUC=0.723). Conclusion. The differential diagnosis between ABU and UTIs includes a comprehensive approach based on the analysis of characteristic clinical symptoms, instrumental and microbiological data, as well as additional laboratory biomarkers.